Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Net Cash Flow (2024 - 2025)

Indivior Pharmaceuticals has reported Net Cash Flow over the past 2 years, most recently at -$250.0 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$250.0 million for Q4 2025, down 906.45% from a year ago — trailing twelve months through Dec 2025 was -$123.0 million (down 4200.0% YoY), and the annual figure for FY2025 was -$123.0 million, down 4200.0%.
  • Net Cash Flow for Q4 2025 was -$250.0 million at Indivior Pharmaceuticals, down from -$62.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for INDV hit a ceiling of $136.0 million in Q2 2025 and a floor of -$250.0 million in Q4 2025.